SAN RAMON, Calif., June 24, 2020—CooperVision has hired Justin Kwan, OD, FAAO, as Senior Manager, Myopia Management in its Professional & Academic Affairs group. In this newly created role, Dr. Kwan will be responsible for supporting the growth of the company’s myopia management business across North America. This includes its Brilliant Futures™ Myopia Management Program featuring MiSight® 1 day, the first and only FDA-approved product1 clinically proven to slow the progression of myopia when initially prescribed for children 8-12 years old* in the United States.
Dr. Kwan will lead the roll-out and provide support of myopia management programs in partnership with eye care practitioners (ECPs) across the United States and Canada. He will work within CooperVision to help define and develop the myopia management strategy including key focus areas, major events, clinical papers, training plans, presentations, and marketing collateral, and ensure cross-functional alignment. In addition to helping develop strategic plans and initiatives, Dr. Kwan will also work to further deepen relationships with ECPs, schools and colleges of optometry, and other industry leaders involved in the field.
“This role requires someone who is extremely knowledgeable about myopia management and can apply that to support ECPs and wearers. We saw Justin’s passion shine through in his commitment to research and other professional engagements,” said Michele Andrews, OD, Senior Director of North America Professional & Academic Affairs at CooperVision. “Justin’s contributions will extend our Brilliant Futures™ Myopia Management Program, and in doing so advance the entire profession and change the lives of children and families for the better.”
Dr. Kwan has more than a decade of professional experience in both practice and educational settings. He comes to CooperVision from Professional Eye Care Center in Niles, Illinois where he served as an optometrist since 2018. Prior to that, Dr. Kwan was on faculty at the Southern California College of Optometry (SCCO). He also completed a dry eye and contact lens research fellowship at SCCO after he graduated from the University of California, Berkeley in 2009. Dr. Kwan is Editor-in-Chief of Clinical and Refractive Optometry, chairs the American Academy of Optometry’s Fellows Doing Research SIG, and is the president of the Chicago North Side Optometric Society.
“Joining CooperVision at this stage is a once in a lifetime opportunity, at a time where the Brilliant Futures™ Myopia Management Program will help define how the profession addresses such a major public health issue. I’m looking forward to becoming part of ECPs’ teams as they grow their myopia management knowledge and practices," said Dr. Kwan.
# # #
1 MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
* When compared to the children in the control group wearing a single vision 1-day contact lens over a 3-year period. Chamberlain P et al. A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. Optom Vis Sci 2019; 96:556-567.
MiSight® 1 day contact lenses are currently approved for sale in the United States, Canada, the United Kingdom, France, Spain, Portugal, Netherlands, Belgium, Germany, Austria, Switzerland, the Nordic Region, Italy, Singapore, Malaysia, Hong Kong, Australia and New Zealand.
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of daily disposable, two-week and monthly contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism, presbyopia and childhood myopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Jamie Palmeroni-Lavis McDougall Communications
email@example.com or +1-585-478-4338